|Ask||11.50 x 2500|
|Day's Range||8.31 - 8.51|
|52 Week Range||5.51 - 10.60|
|PE Ratio (TTM)||-9.09|
|Earnings Date||May 30, 2017 - Jun 5, 2017|
|Dividend & Yield||0.00 (0.00%)|
|1y Target Est||10.00|
SAINT PAUL, Minn., April 20, 2017 /PRNewswire/ -- MGC Diagnostics Corporation (MGCD), a global medical technology company, today announced a new clinical study collaboration with Restech Srl to evaluate the diagnostic accuracy of the forced oscillation technique ("FOT") to detect lung function abnormalities. MGC Diagnostics will sponsor the study and Restech Srl will conduct the study. Measuring lung function is an important component in the diagnostic process for patients with suspected lung function abnormalities such as chronic obstructive pulmonary disease ("COPD") and asthma. Not only does it help identify a specific diagnosis, it also provides valuable information regarding the severity of the condition so that appropriate therapy, including inhaled medications can be prescribed.
Categories: Yahoo Finance Get free summary analysis MGC Diagnostics Corp. reports financial results for the quarter ended January 31, 2017. We analyze the earnings along side the following peers of MGC Diagnostics Corp. – CAS Medical Systems, Inc., Boston Scientific Corporation, Becton, Dickinson and Company, Teleflex Incorporated, Masimo Corporation, Thermo Fisher Scientific Inc. and Dynatronics Corporation (CASM-US, BSX-US, ... Read more (Read more...)
SAINT PAUL, Minn., March 20, 2017 /PRNewswire/ -- MGC Diagnostics Corporation (NASDAQ: MGCD), a global medical technology company, today announced details for its upcoming Annual Meeting of Shareholders ...